An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors

• Status: Completed
• Trial end date: 2015-09-02
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to examine the correlation between UGT1A1 genotypes and the safety of CPT-11 plus platinum analogues (cisplatin, carboplatin and nedaplatin) regimens for patients with lung cancer, cervical cancer, ovarian cancer and gastric cancer.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Co., Ltd.
• Treatments: Carboplatin; Cisplatin; Irinotecan; Nedaplatin

Criteria

Inclusion Criteria:

• Has small cell lung cancer, non-small cell lung cancer, cervical cancer, ovarian cancer and/or gastric cancer

• Has UGT1A1 genotype *1/*6, *1/*28, *6/*6, *28/*28 and *6/*28

• Is receiving CPT-11 plus platinum analogue (cisplatin, carboplatin and nedaplatin) regimens (with or without molecular targeted agents)

Exclusion Criteria:

• Has contraindication for CPT-11

• Has an Eastern Cooperative Oncology Group (ECOG) performance score (PS) of 3-4